Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego

blonca9
Oct 27, 2024
1 min read

Updated: Oct 28, 2024

Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR Stabilization, as well as reductions in Gd-IgA1, hematuria, and proteinuria.

Recent Posts

See All

CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction

Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions

AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy

Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight